A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
A091903 is reopened to new patient accrual to Pre-registration of Advanced Arm 3, effective March 17, 2016.
